Compare BioNano Genomics Inc (BNGO) vs ServiceNow Inc (NOW) Price & Performance

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

ServiceNow (NOW) trades at $111.26, up 3.3% on the day, with a bullish technical signal and strong fundamental growth. Revenue grew to $13.28B in 2025, with net income of $1.75B, though valuation ratios like P/E of 62.41 are elevated. Recent news highlights AI-driven growth opportunities, with the stock gaining 41% in May 2026 (Fool, 2026-06-03).

The outlook remains positive with an 85.51% analyst buy rating and a $137.41 consensus price target, implying significant upside. Risks include high valuation sensitivity and competitive pressures in enterprise AI. Cash flow trends show operational strength, but 2026 projections indicate potential net outflow, warranting monitoring.